Table 1.
Group designation, demographics, and clinical characterization of the study populations.
| Age | Time to Last Event # (days) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No. | Group | Type of SARS-CoV-2 Exposure | Individuals (n) |
Female (%) |
Range | Mean | SD * | Range | Median |
| 1 | A | Non-exposed | 25 | 16 (64) | 19–68 | 51 | 13 | n.a. | |
| 2 | B1 | Wuhan-Hu-1 Convalescent only (Visit 1) | 25 | 10 (40) | 22–76 | 49 | 15 | 37–246 | 61 |
| 3 | B2 | Wuhan-Hu-1 Convalescent only (Visit 2) | 25 | 9 (36) | 18–78 | 49 | 15 | 248–306 | 265 |
| 4 | B3 | Wuhan-Hu-1 Convalescent + 1X Vaccinated | 11 | 5 (45) | 22–77 | 49 | 19 | 20–89 | 35 |
| 5 | B4 | Wuhan-Hu-1 Convalescent + 2X Vaccinated | 4 | 2 (50) | 39–68 | 49 | 13 | 21–103 | 43 |
| 6 | C1 | AstraZeneca 1X Vaccinated | 17 | 13 (76) | 22–61 | 40 | 14 | 21–29 | 22 |
| 7 | C2 | AstraZeneca 2X Vaccinated | 21 | 14 (67) | 22–59 | 40 | 13 | 96–188 | 125 |
| 8 | C3 | AstraZeneca 2X + 1X mRNA Vaccinated | 22 | 16 (73) | 24–69 | 37 | 14 | 23–134 | 99 |
| 9 | D1 | 2X mRNA Vaccinated | 13 | 5 (38) | 21–85 | 49 | 18 | 21–213 | 49 |
| 10 | D2 | 3X mRNA Vaccinated | 27 | 15 (56) | 21–68 | 39 | 14 | 20–122 | 59 |
| 11 | E | 3X Vaccinated + Omicron breakthrough | 14 | 7 (50) | 23–62 | 38 | 13 | 22–74 | 27 |
* Standard deviation; # Event refers to vaccination or infection; Inclusion criterium was ≥20 days since last exposure by infection or vaccination; No., number; n.a., not applicable.